Leiderdorp, Netherlands

Thomas Alfred Profitlich

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Thomas Alfred Profitlich: Innovator in Pharmaceutical Composition

Introduction

Thomas Alfred Profitlich is a notable inventor based in Leiderdorp, Netherlands. He has made significant contributions to the field of pharmaceuticals, particularly in the development of solid dosage forms for medications.

Latest Patents

Profitlich holds a patent for a pharmaceutical composition that includes bendamustine, a drug used in cancer treatment. His invention focuses on solid dosage forms suitable for oral administration. The composition comprises bendamustine or a pharmaceutically acceptable ester, salt, or solvate thereof as an active ingredient, along with at least one pharmaceutically acceptable excipient. This excipient is a saccharide selected from various types, including monosaccharides, disaccharides, oligosaccharides, and saccharide alcohols. The weight ratio of the active ingredient to the saccharide excipient(s) is maintained in the range of 1:1-5. This innovation enhances the delivery and effectiveness of bendamustine in treating patients.

Career Highlights

Profitlich is currently associated with Astellas Deutschland GmbH, where he continues to work on innovative pharmaceutical solutions. His expertise in the field has led to advancements that benefit both the industry and patients.

Collaborations

Throughout his career, Profitlich has collaborated with esteemed colleagues, including Jeffrey Colledge and Ulrich Patzak. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Thomas Alfred Profitlich is a distinguished inventor whose work in pharmaceutical compositions has made a significant impact in the medical field. His patent for solid dosage forms of bendamustine exemplifies his commitment to improving patient care through innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…